ORKA
Oruka Therapeutics, Inc.
$84.40
-0.10 (-0.12%)
At close · Jul 8
Market Cap
$5.09B
Shares
60,312,101
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2023
Net Income
-$105.43M
-25.9%
FY2025
Diluted EPS
-$3.87
+12.8%
FY2024
Operating Cash Flow
-$88.21M
-52.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | |
| $109.86M | $100.64M | $75.06M | $1.01M | $4.75M | $13.83M | $4.99M | $1.83M | $4.24M | $14.08M | $12.35M | $7.06M | $5.63M | $45.61M | $42.68M | $41.59M | |
| $23.54M | $21.41M | $13.06M | $6.28M | $5.85M | $5.5M | $4.77M | $3.98M | $3.88M | $4.64M | $4.27M | $4.39M | $4.07M | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $46.6M | $42.58M | $39.36M | |
| — | — | — | $15K | $20K | $16K | $8000 | $18K | $22K | $27K | $24K | $19K | $12K | $1.8M | $43K | $1.74M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $2.41M | $2.41M | $2.41M | |
| $133.4M | $122.05M | $88.12M | $7.3M | $10.6M | $19.34M | $9.77M | $5.81M | $8.12M | $18.71M | $16.61M | $11.46M | — | $106.08M | $99.14M | $94.82M | |
| — | — | — | — | — | — | — | — | — | — | — | — | $9.69M | — | — | — | |
| -$133.4M | -$122.05M | -$88.12M | -$7.3M | -$10.6M | -$19.34M | -$9.77M | -$5.81M | -$8.12M | -$18.71M | -$16.61M | -$11.46M | -$9.69M | -$106.08M | -$99.14M | -$94.82M | |
| — | — | — | -$7.28M | -$10.58M | -$19.32M | -$9.76M | -$5.8M | -$8.1M | -$18.69M | -$16.59M | -$11.44M | -$9.68M | -$104.28M | -$99.1M | -$93.09M | |
| — | $1.47M | $1.47M | — | — | $9000 | $9000 | $7000 | $8000 | $6000 | $4000 | $4000 | $3000 | — | — | — | |
| $17.14M | $16.63M | $5.86M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $17.15M | $16.62M | $4.4M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$105.43M | -$83.72M | — | — | -$19.32M | -$9.75M | -$5.65M | -$7.96M | -$18.55M | — | — | — | -$77.21M | -$70.28M | -$65.96M | |
| $0 | — | — | $0 | $0 | -$9000 | -$9000 | -$167K | -$31K | -$61K | $0 | $0 | $0 | -$2.28M | -$2.28M | -$2.28M | |
| -$116.25M | -$105.43M | -$83.72M | -$5.34M | -$9.93M | -$19.32M | -$9.74M | -$5.48M | -$7.93M | -$18.49M | -$16.44M | -$11.45M | -$9.69M | -$74.93M | -$67.99M | -$63.67M | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$9.69M | -$77.99M | -$69.02M | -$64.7M | |
| -$116.73M | -$104.85M | -$83.77M | — | — | — | — | -$5.48M | -$7.93M | -$18.47M | -$16.46M | — | — | — | — | — | |
| USD/shares | — | — | -$3.87 | -$4.44 | -$8.28 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | — | -$3.87 | -$4.44 | -$8.28 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | 16.79M | 1.2M | 1.2M | 1.16M | 392.52K | 110.1K | 1.15M | 869.28K | 755.62K | 524.11K | 1.71M | 719.31K | 185.52K | — |
| shares | — | — | 16.79M | 1.2M | 1.2M | 1.16M | 392.52K | 110.1K | 1.15M | 869.28K | 755.62K | 524.11K | 1.71M | 719.12K | 185.29K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.